Xofluza (Baloxavir Marboxil) is an innovative anti-influenza virus drug that exerts therapeutic effects with a single oral dose, demonstrating significant clinical advantages.

Dosage and Administration of Xofluza (Baloxavir Marboxil)

Regular Therapeutic Dosage

The regular recommended dosage of Xofluza is a single oral administration.

Specific dosages are stratified by age and weight: For adults and adolescents aged 12 years and above, 80mg is recommended for those weighing ≥80kg, and 40mg for those weighing <80kg.

For children under 12 years old, dosage calculation is more refined: 40mg for those weighing ≥40kg; 20mg for those weighing ≥20kg and <40kg; 10mg for those weighing ≥10kg and <20kg.

For infants weighing <10kg, the dosage should be accurately calculated by weight, with a recommended dose of 1mg/kg.

Prophylactic Dosage

For prophylaxis, Xofluza also uses a single oral administration mode.

The dosage standard is consistent with the therapeutic dosage: For adults and adolescents aged 12 years and above, 80mg for those weighing ≥80kg, and 40mg for those weighing <80kg.

Prophylactic administration should start within 2 days after exposure to influenza patients; the effectiveness of administration beyond 48 hours has not been supported by data.

The preventive effect after drug administration lasts for a maximum of 10 days; the preventive effect beyond this period has not been confirmed.

Dosage Adjustment of Xofluza (Baloxavir Marboxil)

Precautions for Dosage Form Selection

Bioequivalence between 10mg tablets and 20mg tablets has not been confirmed.

When a dose of 20mg or more is required, combining 10mg tablets is strictly prohibited; the corresponding single dosage form should be selected instead.

20mg tablets and 2% granules have been confirmed to be bioequivalent at the same dose, providing more options for clinical medication.

Grasp of Administration Timing

Therapeutic administration should start as soon as possible after symptom onset, ideally within 48 hours.

Data on the effectiveness of administration beyond this time window are insufficient.

Use in Special Populations for Xofluza (Baloxavir Marboxil)

Detailed Rules for Pediatric Patients

Pediatric medication requires extra caution, especially for young children.

Data show that the younger the child, the higher the frequency of low-susceptibility virus strains.

For pediatric patients weighing <20kg, the possibility of using other anti-influenza virus drugs should be prioritized before using Xofluza.

For neonates and infants, special attention should be paid to the risk of vitamin K deficiency; it should be confirmed that vitamin K preparations have been administered in accordance with domestic guidelines before medication.

Patients with Hepatic Impairment

No targeted safety clinical trials have been conducted for patients with severe hepatic impairment.

In patients with moderate hepatic impairment, drug metabolism will change to a certain extent, requiring enhanced monitoring.

Pregnant and Lactating Women

Pregnant women or women of childbearing potential should consider using the drug only when the therapeutic benefits outweigh the potential risks.

Although no teratogenicity was observed in animal experiments, adverse reactions such as miscarriage may occur at high doses.

Lactating women need to comprehensively evaluate the necessity of treatment and the benefits of breastfeeding to decide whether to continue breastfeeding or temporarily discontinue the drug.